Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2021-12-16 Foreign Filer Report
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2021-12-16 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated December 16, 2021, announcing that the first patient has been dosed in a Phase 1/2 clinical trial for a drug candidate (IPH6101/SAR443579). It details the scientific background, the collaboration with Sanofi, and the triggering of a milestone payment. This type of announcement, focusing on clinical trial progress and partnership updates, is characteristic of an Investor Presentation (IP) or a general press release that doesn't fit the specific financial report categories (like 10-K, IR, ER). Since it provides detailed scientific and strategic information aimed at investors regarding pipeline progress, 'Investor Presentation' (IP) is the most fitting category among the specific options, although it functions as a press release. Given the detailed nature about the drug platform (ANKETTM) and collaboration terms, it goes beyond a simple 'Earnings Release' (ER) or 'Regulatory Filing' (RNS) fallback, leaning towards investor communication material.
2021-12-16 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated December 16, 2021, announcing that the first patient has been treated in a Phase 1/2 clinical trial (NCT05086325) for the drug IPH6101/SAR443579. It details the scientific rationale, collaboration with Sanofi, and the trigger of a milestone payment. This type of announcement, focusing on clinical trial progress, scientific updates, and partnership milestones, is characteristic of an Investor Presentation (IP) or a general press release related to R&D progress. Since it is a detailed announcement of clinical progress and scientific data (including preclinical results and platform details), it aligns best with the Investor Presentation (IP) category, which often includes such detailed scientific and strategic updates, even if presented as a press release. It is not a formal regulatory filing like a 10-K or an Earnings Release (ER). It is too detailed for a simple Report Publication Announcement (RPA).
2021-12-16 French
INNATE PHARMA S.A. FORM 6-K
Foreign Filer Report
2021-12-09 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is a press release from Innate Pharma dated December 9, 2021, announcing that preliminary data on a combination therapy (monalizumab, cetuximab, and durvalumab) for head and neck cancer will be presented at the ESMO Immuno-Oncology 2021 congress. It details key clinical results (ORR, median survival) and provides context about the drug and the company. This format—an announcement of clinical data presentation and key highlights—is characteristic of an Earnings Release (ER) or a general press release detailing operational/clinical progress. Since it focuses on clinical trial results and data presentation rather than a full quarterly financial review (IR) or a formal management discussion (MDA), and it is an initial announcement of results being shared publicly (even if at a conference), 'Earnings Release' (ER) is the most appropriate fit among the options for summarizing key performance/operational updates, although 'Regulatory Filing' (RNS) could also apply if it were a mandatory disclosure. Given the structure focusing on trial data and the announcement of a presentation, ER is chosen as it often encompasses significant operational/clinical milestones announced via press release. FY 2021
2021-12-09 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated December 9, 2021, announcing that data from a clinical trial (Phase 2 expansion cohort) regarding the combination of monalizumab, cetuximab, and durvalumab will be presented at the ESMO Immuno-Oncology Congress 2021. It details key data highlights (response rates, survival) and provides presentation details. This format—announcing clinical data presentation and providing key results via a press release—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is announcing results/updates, ER is the closest fit for summarizing key period performance/developments, although it is specifically clinical data. Given the context of a biotech company announcing clinical trial results and presentation dates, it functions as a major operational/results update. It is not a formal regulatory filing like a 10-K or a simple notification like RPA. Therefore, Earnings Release (ER) is the most appropriate classification for a press release detailing key operational/trial results.
2021-12-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.